Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Toric IOL outperforms comparable spherical lens in FDA trial
San Diego - The AcrySof Toric IOL (Alcon Laboratories, Fort Worth, TX) is outperforming a comparable spherical IOL in uncorrected visual acuity (UCVA) levels and the low level of residual astigmatism. The interim safety and efficacy results of the FDA clinical trial of the AcrySof Toric IOL were presented here at the annual meeting of the American Society of Cataract and Refractive Surgery.
Related Videos
Related Content
